Switch Language
Alt tag

 

 

Gadovist®: A Clear Choice – From Diagnosis to Care

For patients requiring a clear diagnosis to unexpected health issues, Gadovist® offers an exceptional combination of safety and accuracy.

 

 

Gadovist® - Make Every Scan Count

At Bayer in Radiology, we are dedicated to providing solutions that help ensure you deliver the best care possible to your patients. Watch the video below to learn more about the unique properties of Gadovist® which make it Canada's most used magnetic resonance (MR) contrast agent. 

Gadovist-Make every scan count

YYMMDD Author/Uploaded by

 

How Gadovist® Works

The active ingredient in Gadovist® is gadobutrol. Gadobutrol contains gadolinium (Gd3+) which is firmly bound in a macrocyclic complex. Gadolinium is a rare earth element, which causes contrast enhancement in MRI scans. The mode of action is the same as with all currently marketed extracellular Gd-containing products. The high concentration combined with high relaxivity of Gadovist® result in highest T1 shortening per mL, allowing Gadovist® to deliver excellent image quality.2,3

Gadovist®, as a macrocyclic agent, belongs to the class with high kinetic stability and therefore, low, almost negligible, release of gadolinium.4 Gadovist® 1.0 has higher gadolinium concentration (1.0 mmol/mL) than all the other marketed extracellular gadolinium-based contrast agents (0.5 mmol/mL).5-7

Gadovist®: The Most Indications in Canada

With the most on-label indications of any MR macrocyclic contrast agent in Canada, Gadovist® is uniquely indicated for detection of very small lesions and for visualization of tumors that do not readily take up contrast media.5 Because of its higher sensitivity compared to mammography, contrast-enhanced MRI can also improve breast cancer detection, especially in women with dense breasts – and only Gadovist® is indicated for use as a macrocyclic MR contrast agent in breast exams.5-9

Alt tag

Gadovist®: Proven Safety and Accuracy

  • The safety profile of gadobutrol is well established in more than 6,800 patients in clinical trials and 75 million administrations over 23 years of post-marketing experience in a variety of indications10,11
  • Its safety has also been demonstrated in clinical studies involving a wide variety of patients, including those with renal insufficiency.10,12
  • Gadovist® has been shown to have improved sensitivity and accuracy for detection of malignant disease and better visualization of enhancing brain lesions compared to other macrocyclic MRI agents.13,14 It has also been proven to be as safe for use in children without requiring a dose adjustment.5
  • In a study of 27 patients with brain metastases, for two patients, the use of Gadovist® allowed for the detection of lesions that went undetected with a lower relaxivity agent.15
Alt tag

References: 

  1. MR Contrast Report, Q1 2020 based on data of Global Contrast Media Industry Group through W&W, Inc.
  2. Szomolanyi Q, et al. Comparison of the relaxivities of macrocyclic gadolinium-based contrast agents in human plasma at 1.5, 3, and 7 T, and Blood at 3 T. Invest Radiol. 2019;54(9):559-564.
  3. Anzalone N, et al. Optimizing contrast-enhanced magnetic resonance imaging characterization of brain metastases: Relevance to stereotactic radiosurgery. Neurosurgery. 2013;72:691-701.
  4. Frenzel T, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;43(12):817-828.
  5. Gadovist® Product Monograph. September 30, 2021.
  6. Dotarem meglumine Product Monograph. April 23, 2018.
  7. ProHance Product Monograph. March 24, 2022.
  8. Emaus MJ, et al. MR imaging as an additional screening modality for the detection of breast cancer in women aged 50-75 years with extremely dense breasts: The DENSE trial study design. Radiology. 2015;277(2):527-537.
  9. Bakker MF, et al. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 2019:381(22):2091-2102.
  10. Endrikat J, et al. Safety of gadobutrol: Results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol. 2016;51(9):537-543.
  11. Barkhausen J, et al. Diagnostic efficacy of contrast-enhanced breast MRI versus X-ray mammography in women with different degrees of breast density. Acta Radiologica. 2021;62(5):586-593.
  12. Michaely HJ, et al. Gadobutrol in renally impaired patients: Results of the GRIP study. Invest Radiol. 2017;52(1):55-60.
  13. Anzalone N, et al. Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1mmol Gd/kg body weight in a clinical setting. Eur J Radiol. 2011;82:139-145.
  14. Gutierrez JE. Safety and efficacy of gadobutrol for contrast-enhanced magnetic resonance imaging of the central nervous system: Results from a multicenter, double-blind, randomized, comparator study. Magnetic Resonance Insights. 2015;8:1-10.
  15. Anzalone N, et al. Detection of cerebral metastases on magnetic resonance imaging intraindividual comparison of gadobutrol with gadopentate dimeglumine. Acta Radiologica. 2009;50:933-940.